NEW DELHI – In twin developments, an Indian patent office rejected U.S.-based Gilead Sciences Inc.'s patent application for its blockbuster hepatitis C virus (HCV) drug Sovaldi (sofosbuvir), leaving the door open for low-cost generic versions of a drug that is currently out of reach of most Indian patients. However, the court also granted regulatory approval for the drug, making India the first Asian country to do so.